Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial Publisher Pubmed



Shalbafan M1 ; Malekpour F1 ; Tadayon Najafabadi B2 ; Ghamari K2 ; Dastgheib SA3 ; Mowla A3 ; Shirazi E1 ; Eftekhar Ardebili M1 ; Ghazizadehhashemi M1 ; Akhondzadeh S2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Psychiatric Research Center, Tehran University of Medical, Tehran, Iran
  3. 3. Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Source: Journal of Psychopharmacology Published:2019


Abstract

Background: About 50% of obsessive-compulsive disorder patients still suffer significant symptoms even after the recommended first-line therapy. This demonstrates the necessity to investigate strategies to improve alleviation of symptoms. Objective: The main objective of this study was to investigate the efficacy of a 5-hydroxytryptophan 3 receptor antagonist, tropisetron, as an adjuvant therapy to selective serotonin reuptake inhibitors, in ameliorating obsessive-compulsive disorder symptoms. Methods: Men and women between the ages of 18–60 years diagnosed with obsessive-compulsive disorder, based on DSM5, who had a Yale-Brown obsessive compulsive scale score of more than 21 were recruited in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either tropisetron (5 mg twice daily) and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4) or placebo and fluvoxamine. The primary outcome of interest in this study was the Yale-Brown obsessive compulsive scale total score decrease from baseline. Results: One hundred and eight participants were equally randomized into two groups; 48 participants in each group finished the trial. The Yale-Brown obsessive compulsive total score significantly dropped in both groups while the tropisetron group participants experienced a significantly higher decrease in their scores (Greenhouse-Geisser F(1.53–65.87)=3.516, p-value=0.04). No major adverse effect was observed in any of the groups. Conclusion: This trial showed a significant efficacy for tropisetron over placebo in treatment of obsessive-compulsive disorder symptoms when added to fluvoxamine. © The Author(s) 2019.
Related Docs
View other Related Docs
1. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)
2. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)
3. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)
4. Correlations Between Single Nucleotide Polymorphisms in Obsessive-Compulsive Disorder With the Clinical Features or Response to Therapy, Journal of Psychiatric Research (2023)
5. Minocycline Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2016)
6. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)
7. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind, Randomized Clinical Trial, Iranian Journal of Psychiatry (2017)
8. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (27)
Farzin Rezaei (5)
Other Related Docs
9. N-Acetylcysteine Augmentation Therapy for Moderate-To-Severe Obsessive-Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Pharmacy and Therapeutics (2016)
10. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial, Pharmacopsychiatry (2018)
11. Patients With Ocd Report Lower Quality of Life After Controlling for Expert-Rated Symptoms of Depression and Anxiety, Psychiatry Research (2018)
12. Repetitive Transcranial Magnetic Stimulation (Rtms) Improves Symptoms and Reduces Clinical Illness in Patients Suffering From Ocd - Results From a Single-Blind, Randomized Clinical Trial With Sham Cross-Over Condition, Journal of Psychiatric Research (2015)
13. Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review, Journal of Medicinal Plants (2019)
14. The Efficacy of Aripiprazole Versus Risperidone As Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Double Blind Clinical Trial, Iranian Red Crescent Medical Journal (2018)
15. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)
16. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Clinical Neuropharmacology (2023)
17. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Clinical Neuropharmacology (2019)
18. Celecoxib As an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial, Pharmacopsychiatry (2015)
19. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study, Pharmacopsychiatry (2016)
20. Naproxen Adjunct to Fluoxetine for Moderate-To-Severe Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Psychiatry and Clinical Neurosciences (2024)
21. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)
22. Repetitive Transcranial Magnetic Stimulation Improved Symptoms of Obsessive-Compulsive Disorder, But Also Cognitive Performance: Results From a Randomized Clinical Trial With a Cross-Over Design and Sham Condition, Neuropsychobiology (2016)
23. A Systematic Review and Meta-Analysis: Memantine Augmentation in Moderate to Severe Obsessive-Compulsive Disorder, Psychiatry Research (2019)
24. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)
25. Glutamatergic Medications As Adjunctive Therapy for Moderate to Severe Obsessive-Compulsive Disorder in Adults: A Systematic Review and Meta-Analysis, BMC Pharmacology and Toxicology (2021)
26. Beneficial Effects of Physical Activity on Depressive and Ocd-Like Behaviors in the Male Offspring of Morphine-Abstinent Rats, Brain Research (2020)
27. Medicinal Plants in the Treatment of Obsessive-Compulsive Disorder: A Review, Current Drug Discovery Technologies (2021)
28. Crocus Sativus L. Versus Methylphenidate in Treatment of Children With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study, Journal of Child and Adolescent Psychopharmacology (2019)
29. A Comparative, Single-Blind, Randomized Study on Quetiapine and Aripiperazole Augmentation in Treatment of Selective Serotonin Reuptake Inhibitor Refractory Obsessive-Compulsive Disorder, Canadian Journal of Physiology and Pharmacology (2020)
30. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
31. Validation for Persian Versions of “Desire for Drug Questionnaire” and “Obsessive Compulsive Drug Use Scale” in Heroin Dependents, Archives of Iranian Medicine (2016)
32. Effects of Antidepressants on Brain Structure and Function in Patients With Obsessive-Compulsive Disorder: A Review of Neuroimaging Studies, Psychiatry Research - Neuroimaging (2024)
33. Obsessive–Compulsive Disorder, Which Genes? Which Functions? Which Pathways? an Integrated Holistic View Regarding Ocd and Its Complex Genetic Etiology, Journal of Neurogenetics (2017)
34. Involvement of Pparγ in the Protective Action of Tropisetron in an Experimental Model of Ulcerative Colitis, Immunopharmacology and Immunotoxicology (2016)
35. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)
36. Vortioxetine Effects on Quality of Life of Irritable Bowel Syndrome Patients: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Pharmacy and Therapeutics (2020)
37. Efficacy of Melatonin As an Adjunct in the Treatment of Acute Mania: A Double-Blind and Placebo-Controlled Trial, International Clinical Psychopharmacology (2020)
38. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)
39. Disclosing Common Biological Signatures and Predicting New Therapeutic Targets in Schizophrenia and Obsessive–Compulsive Disorder by Integrated Bioinformatics Analysis, BMC Psychiatry (2023)
40. Repetitive Transcranial Magnetic Stimulation Improved Symptoms of Obsessive-Compulsive Disorders But Not Executive Functions: Results From a Randomized Clinical Trial With Crossover Design and Sham Condition, Neuropsychobiology (2017)
41. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
42. The Effect of Virtual Reality on Emotional Response and Symptoms Provocation in Patients With Ocd: A Systematic Review and Meta-Analysis, Frontiers in Psychiatry (2022)
43. Tropisetron But Not Granisetron Ameliorates Spatial Memory Impairment Induced by Chronic Cerebral Hypoperfusion, Neurochemical Research (2020)
44. Efficacy and Safety of Tipepidine As Adjunctive Therapy in Children With Attention-Deficit/Hyperactivity Disorder: Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2019)
45. Cerebellar Microstructural Abnormalities in Obsessive–Compulsive Disorder (Ocd): A Systematic Review of Diffusion Tensor Imaging Studies, Cerebellum (2024)